Engineered immune cells take aim at stubborn leukemia

NCT ID NCT05995041

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 1 trial tests a new type of immunotherapy called universal CAR T cells in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The cells are engineered to recognize and attack leukemia cells by targeting four different proteins (CLL-1, CD33, CD38, and CD123). The study aims to see if this treatment is safe and whether it can shrink tumors or lead to remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: universal CAR T cells targeting CLL-1, CD33, CD38, and CD123
What this could lead to: If successful, this approach could offer a new treatment option for patients with hard-to-treat acute myeloid leukemia, potentially improving remission rates.
What could go wrong: This is an early phase 1 trial with a small number of participants, so safety and effectiveness are not yet proven. CAR T cell therapy can cause severe side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Shenzhen Geno-Immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.